Biodexa Pharmaceticals
Yahoo Finance • 21 days ago
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0... Full story
Yahoo Finance • 25 days ago
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in... Full story
Yahoo Finance • last month
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP... Full story
Yahoo Finance • last month
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies... Full story
Yahoo Finance • 2 months ago
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its re... Full story
Yahoo Finance • 2 months ago
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company develo... Full story
